共 50 条
- [31] Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trialLANCET, 2021, 397 (10273): : 475 - 486Gordon, Kenneth B.Foley, PeterKrueger, James G.Pinter, AndreasReich, KristianVender, RonaldVanvoorden, VeerleMadden, CynthiaWhite, KatyCioffi, ChristopherBlauvelt, Andrew
- [32] Efficacy and safety of ixekizumab in a phaseIII, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS)BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (02) : 231 - 241Paller, A. S.Seyger, M. M. B.Alejandro Magarinos, G.Bagel, J.Pinter, A.Cather, J.Keller, S.Rodriguez Capriles, C.Gontijo Lima, R.Gallo, G.Little, C. A.Edson-Heredia, E.Li, L.Xu, W.Papp, K.
- [33] Efficacy and Safety of Adalimumab among Patients with Moderate to Severe Psoriasis with Co-MorbiditiesSubanalysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase III TrialAmerican Journal of Clinical Dermatology, 2011, 12 : 51 - 62Alexa B. KimballArielle G. BensimonAnnie GuerinAndrew P. YuEric Q. WuMartin M. OkunYanjun BaoShiraz R. GuptaParvez M. Mulani
- [34] Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL StudyJOURNAL OF DRUGS IN DERMATOLOGY, 2017, 16 (08) : 801 - 808Strober, BruceBagel, JerryLebwohl, MarkGold, Linda SteinJackson, J. MarkChen, RongdeanGoncalves, JoanaLevi, EugeniaDuffin, Kristina Callis
- [35] Efficacy and safety of certolizumab pegol, in patients with chronic plaque psoriasis: Preliminary results of a randomized, double-blind, placebo-controlled trialANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 251 - 251Reich, K.Tasset, C.Ortonne, J.
- [36] Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase 3, randomized, controlled trial (ESTEEM 2)JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB164 - AB164Paul, CarleCrowley, JeffreyCather, JenniferGooderham, MelindaDay, RobertMrowietz, UlrichPoulin, Yves
- [37] Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled studyJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 73 (02) : 331 - 333Dogra, SunilKrupashankarBudamakuntla, LeelavathySrinivas, C. R.Khopkar, UdayGupta, SandeshShetty, NarendraPratap, Dasiga Venkata SubrahmanyaGopal, M. G.Rao, T. NarayanaGarg, VijaySumathy, T. K.Saraswat, AbirBhat, RameshKura, MahendraPandey, NeerajShah, RadhaKrishna, Kotla SaiPadmaja, DalavaiManmohan, G.Ramakrishnan, M. S.Barve, AbhijitMontero, Enrique
- [38] Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled studyJOURNAL OF DERMATOLOGY, 2018, 45 (09): : 1053 - 1062Ohtsuki, MamitaroKubo, HiroshiMorishima, HitomiGoto, RyosukeZheng, RichuanNakagawa, Hidemi
- [39] Phase 1b randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of GLPG3667 in patients with moderate-to-severe plaque psoriasisJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB92 - AB92Thaci, DiamantMolnar, JuditTimmis, Helen
- [40] Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trialCHINESE MEDICAL JOURNAL, 2012, 125 (11) : 1845 - 1851Yang Hai-zhenWang KeJin Hong-zhongGao Tian-wenXiao Sheng-xiangXu Jin-huaWang Bao-xiZhang Fu-renLi Chun-yangLiu Xiao-mingTu Cai-xiaJi Su-zhenShen YangZhu Xue-jun